License Agreements (Details Narrative) - Accu-Break Pharmaceuticals, Inc. [Member] - License Agreement [Member] - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Jun. 30, 2019 |
Sep. 18, 2018 |
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Payment to license | $ 30,000 | $ 35,000 | $ 35,000 | |
| Capitalized cost of intangible assets | $ 65,000 | |||
| Impairment of licenses | $ 65,000 | |||
| Value of common stock shares | $ 35,000 | |||
| X | ||||||||||
- Definition Capitalized cost of intangible assets. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|